We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 14, 2019

Polatuzumab Vedotin in Relapsed/Refractory DLBCL

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol 2019 Nov 06;[EPub Ahead of Print], LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, S Assouline, TM Kim, WS Kim, M Ozcan, J Hirata, E Penuel, JN Paulson, J Cheng, G Ku, MJ Matasar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading